empr.com
Tremfya Approved for Moderately to Severely Active Crohn Disease
This is a new FDA approval of an IL-23 inhibitor (guselkumab) for adults with moderately to severely active Crohn disease, adding another biologic treatment option. It’s notable because guselkumab offers both IV and subcutaneous induction routes, which may affect how treatment is started and delivered.
Adults with moderate-to-severe Crohn disease, patients who have had inadequate response to other biologics or immunomodulators, clinicians treating IBD, and patients interested in IV induction options for biologic therapy.
What To Know
FDA approved Tremfya (guselkumab), an IL-23 inhibitor, for adults with moderately to severely active Crohn disease. The approval was based on phase 3 trials (GALAXI 2, GALAXI 3, and GRAVITI) that evaluated IV and subcutaneous induction regimens and showed greater rates of clinical remission and endoscopic response with guselkumab versus placebo.
The drug is available for IV induction by a health care provider or SC induction/maintenance by patient or caregiver after training. Common adverse reactions reported included respiratory tract infections, abdominal pain, injection-site reactions, headache, fatigue, arthralgia, diarrhea, and gastroenteritis.
This article summarizes the FDA approval and highlights that Tremfya is currently the only IL-23 inhibitor with both IV and SC induction options for Crohn disease. It references the company news release and prescribing information as the sources for dosing forms and trial results.
If you or your clinician are considering treatment options, this approval expands the biologic choices for moderate-to-severe Crohn disease and may be especially relevant for people who need or prefer an IV induction option. Discuss with your care team whether guselkumab is appropriate given prior treatments, medical history, and potential side effects.
The article reports a regulatory approval based on phase 3 trials; it is not treatment guidance. Safety and efficacy details come from the trials and the product label—discuss individual suitability, dosing, and monitoring with a clinician. The source cites a company news release and the prescribing information.
